“It is a small emergency,” says Amit Bakshi, chairman of Ahmedabad-based drugmaker Eris Lifesciences. He points to the recent decision of Novo Nordisk, the world’s top seller of insulin, to gradually phase out a popular product from India and several other markets as a part of global strategy. Weeks ago, Abbott Labs, the marketing partner of Novo Nordisk, had sent out the missive that had doctors and patients alarmed. It said some pen-filled
As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market
